The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma....
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment - a prospective study of 160 patients. Blood, 63, 468-476. BATAILLE, R-. JOURDAN, M., ZHANG, X.G. & KLEIN, B. (1989). Serum levels of interleukin 6, a potent myeloma cell growth factor, as a ...
a small amount of monoclonal protein is produced, but it does not fulfill criteria for the diagnosis of myeloma. There is no associated anemia, infections, bone disease, or lowering of normal immunoglobulin levels. It is unknown whether this disease will progress. Because MGUS involves no symptoms...
withmultiple myelomawill haveacute kidney injuryat presentation, and the prognosis is worse for those patients with acute kidney injury than those without. Factors contributing to the development of acute kidney injury in multiple myeloma include dehydration,hypercalcemia, and theingestionof nephrotoxic ...
The presenting clinical features, response to treatment and survival duration of 26 consecutive multiple myeloma patients with renal failure at diagnosis were investigated. All but 1 of the patients had high tumour cell mass stage, as identified by one (3 cases) or more (22 cases) of the crite...
Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the depth of post-therapeutic remissi
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can aid in selecting the right treatment at diagnosis. Here we introduce s
Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a next-generation PI, treats RRMM as both a monotherapy and in combination; and ixazomib, the ...
Interactions between multiple myeloma (MM) and bone marrow (BM) are well documented to support tumour growth, yet the cellular mechanisms underlying pain in MM are poorly understood. We have used in vivo murine models of MM to show significant induc
Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.